title: [Fluctuating molecular remission in patients with chronic myeloid leukemia with long term complete cytogenetic response after alpha interferon treatment].
abstract: BACKGROUND
  Alpha interferon can induce complete cytogenetic responses (CGR) in nearly 25% of chronic myeloid leukemia (CML) patients, but few of them obtain molecular responses (i.e. disappearance of the chimeric RNA bcr-abl). The incidence and evolution of this response are not well known.
  
  
  METHODS
  The molecular response has been explored in six CML patients, four in first chronic phase and two in relapse after bone marrow transplantation, who have obtained durable and sustained CGR. Bone marrow samples have been analyzed by double step RT-PCR. Results have been correlated with clinical and karyotype findings.
  
  
  RESULTS
  Twenty nine samples have been studied. Every patient in first chronic phase CML have obtained molecular response, but this response has not been persistent. One of the patients with relapsing CML after showed transient PCR negativity, whereas persistent PCR positivity was detected in the other one.
  
  
  CONCLUSIONS
  Interferon alpha can induce complete molecular responses in CML patients, but in this study this responses have been fluctuant in all the patients.
authors.affiliation: Servicio de Hematología, Hospital Universitario de La Princesa, Madrid.
authors.forename: L F
authors.initials: LF
authors.lastname: Casado
authors.forename: M
authors.initials: M
authors.lastname: Picó
authors.forename: C
authors.initials: C
authors.lastname: Gómez
authors.forename: M T
authors.initials: MT
authors.lastname: Ferro
authors.forename: J M
authors.initials: JM
authors.lastname: Fernández-Rañada
authors.forename: J L
authors.initials: JL
authors.lastname: Steegmann
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D012313:RNA / Q000032:analysis; D012074:Remission Induction
chemical_list: D000970:Antineoplastic Agents; D016898:Interferon-alpha; D012313:RNA; D016044:Fusion Proteins, bcr-abl